This restores the ability of PD-1/PD-L1 antibodies to enhance T-cell attacks on tumor cells, promotes the reconstruction of the immunosuppressive microenvironment into an immune-activating microenvironment, and activates T cells to recognize tumor antigens, thereby exerting anti-tumor effects. The gene discussed is CD274; the disease is neoplasm.